Complex Oncology Center Vratsa EOOD

At Complex Oncology Center Vratsa EOOD, clinical trials in neoplasms focus strongly on breast cancer, including early, advanced, and metastatic disease. These studies are designed to evaluate new treatment options and compare them with established endocrine therapies to help reduce recurrence and improve disease control.

• ER+/HER2- early breast cancer
• Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
• HR-positive HER2-negative metastatic/advanced breast cancer
• Advanced breast cancer

The research reflects a major interest in endocrine-based therapy and in finding more effective approaches for patients whose disease has progressed after prior treatment.

Another key area of work involves advanced solid tumors and broader oncology studies aimed at testing new combinations of anti-cancer therapies. These trials are focused on assessing safety, tolerability, and whether newer treatment strategies can better slow disease progression.

• Advanced solid tumors
• Cancer
• Metastatic breast cancer
• Relapsed or refractory disease

This line of research supports the development of more precise and effective treatment approaches for people with difficult-to-treat cancers.

The site also studies cancer cachexia, a serious metabolic complication seen in advanced cancer. Trials in this nutritional and metabolic diseases area are evaluating therapies intended to improve body weight and address the physical decline associated with cachexia.

• Cancer cachexia
• Cancer-associated cachexia
• Weight loss in cancer
• Metabolic complications of advanced cancer

These studies aim to improve supportive care and quality of life for patients affected by the metabolic burden of cancer.

Clinical research at this hospital and clinic setting also includes several other malignancies, with attention to treatment options for prostate cancer, small cell lung cancer, and lymphoma. The trials are exploring whether new therapies can benefit patients with relapsed, refractory, or treatment-resistant disease.

• Castration resistant prostate cancer
• Small cell lung cancer
• Diffuse large B-cell lymphoma
• Follicular lymphoma

These investigations broaden the center’s oncology portfolio and support efforts to improve outcomes across several aggressive cancer types.